← Back to patent-cliff list
EIK1005
Tier C — Watch / tradeEIK1005
Eikon Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：WRN
Indications (approved)：错配修复基因缺陷型肿瘤, 高微卫星不稳定性癌症, Colorectal cancer, Solid tumour, Oesophageal cancer, Gastric cancer, Endometrial cancer
Regional status
US
Phase II
2026-01-20
EU
Phase II
2026-01-20
China
Phase I
2026-09-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of EIK1005?
Approved indications include: 错配修复基因缺陷型肿瘤, 高微卫星不稳定性癌症, Colorectal cancer, Solid tumour, Oesophageal cancer, Gastric cancer, Endometrial cancer.
When does the EIK1005 patent expire?
No public expiry year is available for EIK1005 yet; this page updates once verified.
How do I get a quote for EIK1005 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29